PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis
USA - NASDAQ:PCRX - US6951271005 - Common Stock
27.12 USD
+0.09 (+0.33%)
27.12 USD
0 (0%)
Taking everything into account, PCRX scores 5 out of 10 in our fundamental rating. PCRX was compared to 195 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of PCRX get a neutral evaluation. Nothing too spectacular is happening here. PCRX has a bad growth rate and is valued cheaply. With these ratings, PCRX could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
PCRX had positive earnings in the past year.
In the past year PCRX had a positive cash flow from operations.
Of the past 5 years PCRX 4 years were profitable.
Each year in the past 5 years PCRX had a positive operating cash flow.
1.2 Ratios
The Return On Assets of PCRX (-8.29%) is better than 68.72% of its industry peers.
PCRX's Return On Equity of -16.82% is fine compared to the rest of the industry. PCRX outperforms 70.77% of its industry peers.
PCRX's Return On Invested Capital of 3.88% is amongst the best of the industry. PCRX outperforms 81.03% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 15.28%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.29% | ||
| ROE | -16.82% | ||
| ROIC | 3.88% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
1.3 Margins
PCRX has a better Operating Margin (9.90%) than 82.56% of its industry peers.
PCRX's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 78.19%, PCRX belongs to the best of the industry, outperforming 84.62% of the companies in the same industry.
PCRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.9% | ||
| PM (TTM) | N/A | ||
| GM | 78.19% |
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
PCRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for PCRX has been reduced compared to 1 year ago.
The number of shares outstanding for PCRX has been increased compared to 5 years ago.
PCRX has a worse debt/assets ratio than last year.
2.2 Solvency
PCRX has an Altman-Z score of 1.69. This is a bad value and indicates that PCRX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.69, PCRX is in the better half of the industry, outperforming 63.08% of the companies in the same industry.
PCRX has a debt to FCF ratio of 4.96. This is a neutral value as PCRX would need 4.96 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 4.96, PCRX belongs to the best of the industry, outperforming 83.59% of the companies in the same industry.
A Debt/Equity ratio of 0.50 indicates that PCRX is not too dependend on debt financing.
The Debt to Equity ratio of PCRX (0.50) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.96 | ||
| Altman-Z | 1.69 |
ROIC/WACC0.45
WACC8.66%
2.3 Liquidity
PCRX has a Current Ratio of 2.38. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.38, PCRX is in line with its industry, outperforming 42.56% of the companies in the same industry.
A Quick Ratio of 1.91 indicates that PCRX should not have too much problems paying its short term obligations.
The Quick ratio of PCRX (1.91) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.91 |
3. Growth
3.1 Past
PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.92%.
The Earnings Per Share has been growing by 13.96% on average over the past years. This is quite good.
Looking at the last year, PCRX shows a very negative growth in Revenue. The Revenue has decreased by -17.68% in the last year.
Measured over the past years, PCRX shows a quite strong growth in Revenue. The Revenue has been growing by 10.73% on average per year.
EPS 1Y (TTM)-1.92%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-16.85%
Revenue 1Y (TTM)-17.68%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.73%
3.2 Future
PCRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.92% yearly.
Based on estimates for the next years, PCRX will show a small growth in Revenue. The Revenue will grow by 6.56% on average per year.
EPS Next Y-9.95%
EPS Next 2Y1.81%
EPS Next 3Y6.01%
EPS Next 5Y5.92%
Revenue Next Year5.46%
Revenue Next 2Y7.74%
Revenue Next 3Y8.08%
Revenue Next 5Y6.56%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 8.86, the valuation of PCRX can be described as very reasonable.
Based on the Price/Earnings ratio, PCRX is valued cheaply inside the industry as 91.79% of the companies are valued more expensively.
PCRX is valuated cheaply when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 8.15 indicates a reasonable valuation of PCRX.
Based on the Price/Forward Earnings ratio, PCRX is valued cheaper than 89.23% of the companies in the same industry.
PCRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.73.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.86 | ||
| Fwd PE | 8.15 |
4.2 Price Multiples
92.82% of the companies in the same industry are more expensive than PCRX, based on the Enterprise Value to EBITDA ratio.
91.28% of the companies in the same industry are more expensive than PCRX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.41 | ||
| EV/EBITDA | 7.53 |
4.3 Compensation for Growth
PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.63
EPS Next 2Y1.81%
EPS Next 3Y6.01%
5. Dividend
5.1 Amount
PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
27.12
+0.09 (+0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners111.46%
Inst Owner Change0.2%
Ins Owners0.8%
Ins Owner Change0.71%
Market Cap1.22B
Analysts76.92
Price Target38.15 (40.67%)
Short Float %14.25%
Short Ratio9.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.06%
Min EPS beat(2)1.99%
Max EPS beat(2)2.13%
EPS beat(4)4
Avg EPS beat(4)5.22%
Min EPS beat(4)1.99%
Max EPS beat(4)9.93%
EPS beat(8)5
Avg EPS beat(8)3.99%
EPS beat(12)6
Avg EPS beat(12)-0.53%
EPS beat(16)8
Avg EPS beat(16)-3.68%
Revenue beat(2)0
Avg Revenue beat(2)-4.46%
Min Revenue beat(2)-5.92%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-2.98%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.49%
Revenue beat(12)1
Avg Revenue beat(12)-2.62%
Revenue beat(16)1
Avg Revenue beat(16)-2.55%
PT rev (1m)-4.1%
PT rev (3m)-3.11%
EPS NQ rev (1m)-2.15%
EPS NQ rev (3m)-25.51%
EPS NY rev (1m)-2.34%
EPS NY rev (3m)0.51%
Revenue NQ rev (1m)-0.66%
Revenue NQ rev (3m)-0.21%
Revenue NY rev (1m)-0.5%
Revenue NY rev (3m)-0.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.86 | ||
| Fwd PE | 8.15 | ||
| P/S | 1.73 | ||
| P/FCF | 10.41 | ||
| P/OCF | 9.06 | ||
| P/B | 1.61 | ||
| P/tB | 3.87 | ||
| EV/EBITDA | 7.53 |
EPS(TTM)3.06
EY11.28%
EPS(NY)3.33
Fwd EY12.27%
FCF(TTM)2.61
FCFY9.61%
OCF(TTM)2.99
OCFY11.04%
SpS15.71
BVpS16.87
TBVpS7.01
PEG (NY)N/A
PEG (5Y)0.63
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.29% | ||
| ROE | -16.82% | ||
| ROCE | 5.71% | ||
| ROIC | 3.88% | ||
| ROICexc | 6.11% | ||
| ROICexgc | 14.17% | ||
| OM | 9.9% | ||
| PM (TTM) | N/A | ||
| GM | 78.19% | ||
| FCFM | 16.59% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
ROICexc(3y)5.86%
ROICexc(5y)7.17%
ROICexgc(3y)13.2%
ROICexgc(5y)24.66%
ROCE(3y)6.13%
ROCE(5y)6.57%
ROICexcg growth 3Y-34.27%
ROICexcg growth 5Y13.31%
ROICexc growth 3Y-4.56%
ROICexc growth 5Y9.22%
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score5
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.96 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 19.4% | ||
| Cap/Sales | 2.47% | ||
| Interest Coverage | 4.34 | ||
| Cash Conversion | 84.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.91 | ||
| Altman-Z | 1.69 |
F-Score5
WACC8.66%
ROIC/WACC0.45
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.92%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-16.85%
EPS Next Y-9.95%
EPS Next 2Y1.81%
EPS Next 3Y6.01%
EPS Next 5Y5.92%
Revenue 1Y (TTM)-17.68%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.73%
Revenue Next Year5.46%
Revenue Next 2Y7.74%
Revenue Next 3Y8.08%
Revenue Next 5Y6.56%
EBIT growth 1Y-39.89%
EBIT growth 3Y-9.76%
EBIT growth 5Y22.27%
EBIT Next Year1.75%
EBIT Next 3Y12.4%
EBIT Next 5Y6.85%
FCF growth 1Y-7.53%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-8.67%
OCF growth 3Y14.64%
OCF growth 5Y21.85%